Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?

Open Cardiovascular Medicine Journal

Volumn 6, Issue 1, 2012, Pages 28-32

  Mitsiou, Eydoxia K ^a   Athyros, Vasilios G ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri I ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Combination; Diabetes mellitus; Fibrates; Microvascular complications; Residual cardiovascular risk; Statin

Indexed keywords

ATORVASTATIN; FENOFIBRATE; FLUINDOSTATIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ALBUMIN BLOOD LEVEL; ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIABETIC AUTONOMIC NEPHROPATHY; DIABETIC AUTONOMIC NEUROPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFECT; DYSLIPIDEMIA; EDITORIAL; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPOLIPEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LEG AMPUTATION; MONOTHERAPY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PARASYMPATHETIC TONE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEIOTROPY; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEINURIA; RISK REDUCTION; SYMPATHETIC TONE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84860669176     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401206010028     Document Type: Editorial

References (54)

1. Sharma RK, Singh VN, Reddy HK. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. Vasc Health Risk Manag 2009; 5: 793-799.
2. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
3. Shepherd J, Kastelein JP, Bittner VA, et al. Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008; 83: 870-879.
4. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
5. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
6. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008; 102 (10 Suppl): 1K-34K.
7. Wanner C, Krane V. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus. Kidney Blood Press Res 2011; 34: 209-217.
8. Pagourelias ED, Gossios TD, Tziomalos K, Karagiannis A, Geleris P, Athyros VG. Residual cardiac risk reduction beyond lipid lowering. Hellenic J Cardiol 2011; 52: 197-203.
9. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
10. O'Flaherty M, Ford E, Allender S, Scarborough P, Capewell S. Coronary heart disease trends in England and Wales from 1984 to 2004; concealed levelling of mortality rates among young adults. Heart 2008; 94: 178-181.
11. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the US from 1980 through 2002: concealed leveling of mortality rates. J Am Coll Cardiol 2007; 50:2128-2132.
12. European Heart Network. European cardiovascular disease statistics. 2011. Brussels. Available from http://www.ehnheart.org (statistics). [Accessed 20 November 2011].
13. Cardiovascular disease statistics. Available from the American Heart Association, http://www.americanheart.org/presenter.jhtml. [Accessed 20 November 2011].
14. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008; 88: 1254-1264.
15. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011; 343: d6898. [doi: 10.1136/bmj.d6898].
16. Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004; 10: 3395-3418.
17. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-244.
18. Hadjadj S, Duly-Bouhanick B, Bekherraz A, et al. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 2004; 30: 43-51.
19. Cusick M, Chew EY, Hoogwerf B, et al. Early Treatment Diabetic Retinopathy Study Research Group: Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS). ETDRS 26. Kidney Int 2004; 66: 1173-1179.
20. Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004; 10: 3395-3418.
21. Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes--insight from the FIELD study. Curr Pharm Des 2009; 15: 537-552.
22. Fioretto P, Dodson PM, Ziegler D, Rosenson RS. Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol 2010; 6: 19-25.
23. Mitsiou EK, Tziomalos K, Anagnostis P, Karagiannis A, Athyros VG. Multifactorial intervention for the prevention of vascular complications of type 2 diabetes. Hellenic J Cardiol 2009; 50: 445-448.
24. Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol 2008; 126: 1740-1747.
25. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-918.
26. The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9 795 people with type 2 diabetes (The FIELD study). Lancet 2005; 366: 1849-1861.
27. Keech AC, Mitchell P, Summanen PA, et al. FIELD Study Investigators: effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697.
28. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
29. Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial. What we learn from subgroup analyses. Diabetes Care 2011; 34 (Suppl 2): S107-S108.
30. Dodson PM. Medical treatment for diabetic retinopathy: do the FIELD microvascular study results support a role for lipid lowering? Pract Diabetes 2008; 25: 76-79.
31. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Should chronic kidney disease be considered as a coronary heart disease equivalent? Curr Vasc Pharmacol 2011. [Epub ahead of print].
32. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-734.
33. Shepherd J, Kastelein JJ, Bittner V, et al. TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51:1448-1454.
34. Shepherd J, Kastelein JJ, Bittner V, et al. Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007; 2: 1131-1139.
35. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145: 117-124.
36. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54: 810-819.
37. Sorof J, Berne C, Siewert-Delle A, Jørgensen L, Sager P; URANUS study investigators. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Res Clin Pract 2006; 72: 81-87.
38. Davis TM, Ting R, Best JD, Donoghoe MW, et al. Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011; 54: 280-290.
39. Drury PL, Ting R, Zannino D, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011; 54: 32-43.
40. Bild DE, Selby JV, Sinnock P, Browner WS, Braveman P, Showstack JA. Lower-xtremity amputation in people with diabetes. Epidemiology and prevention. Diabetes Care 1989; 12: 24-31.
41. Wang W, Balamurugan A, Biddle J, Rollins KM. Diabetic neuropathy status and the concerns in underserved rural communities: challenges and opportunities for diabetes educators. Diabetes Educ 2011; 37: 536-548.
42. Rajamani K, Colman PG, Li LP, et al. FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-1788.
43. Morimoto Y, Bando YK, Shigeta T, Monji A, Murohara T. Atorvastatin prevents ischemic limb loss in type 2 diabetes: role of p53. J Atheroscler Thromb 2011; 18: 200-208.
44. Gulcan E, Gulcan A, Erbilen E, Toker S. Statins may be useful in diabetic foot ulceration treatment and prevention. Med Hypotheses 2007; 69: 1313-1315.
45. Karamitsos DT, Didangelos TP, Athyros VG, Kontopoulos AG. The natural history of recently diagnosed autonomic neuropathy over a period of 2 years. Diabetes Res Clin Pract 1998; 42: 55-63.
46. O'Brien IA, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991; 79: 495-502.
47. Chen HS, Hwu CM, Kuo BI, et al. Abnormal cardiovascular reflex tests are predictors of mortality in Type 2 diabetes mellitus. Diabet Med 2001; 18: 268-273.
48. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25: 612-628.
49. Pop-Busui R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev 2006;22:257-273.
50. Pehlivanidis AN, Athyros VG, Demitriadis DS, Papageorgiou AA, Bouloukos VJ, Kontopoulos AG. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 2001; 157: 463-469.
51. Matsuki A, Nozawa T, Igarashi N, et al. Fluvastatin attenuates diabetes-induced cardiac sympathetic neuropathy in association with a decrease in oxidative stress. Circ J 2010; 7 4: 468-475.
52. Johansen OE, Birkeland KI, Jørgensen AP, et al. Diabetic foot ulcer burden may be modified by high-dose atorvastatin: A 6-month randomized controlled pilot trial. J Diabetes 2009; 1: 182-187.
53. Iliadis F, Didangelos T, Ntemka A, et al. Glomerular filtration rate estimation in patients with type 2 diabetes: creatinine- or cystatin C-based equations? Diabetologia 2011; 54: 2987-2994.
54. Ozsoy RC; van Leuven SI, Kastelein JJP; Arisz L, Koopman MG. The dyslipidemia of chronic renal disease: effects of statin therapy. Curr Opin Lipidol 2006; 17: 659-666.